GlobeNewswire·Nov 12, 2026, 2:09 PM ET

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Genmab A/S disclosed transaction data for managerial employees & their closely associated persons in accordance with EU Market Abuse Regulation.
The company holds power of attorney from these individuals to publish their trading activities in Genmab shares.
Genmab is an international biotechnology firm headquartered in Copenhagen that has developed eight approved antibody medicines over 25 years.
The company maintains a late-stage clinical pipeline featuring bispecific antibodies, antibody-drug conjugates, & immune-modulating antibodies.
Contact information was provided for Marisol Peron (Senior Vice President, Global Communications) & Andrew Carlsen (Vice President, Head of Investor Relations).
The announcement includes standard forward-looking statement disclaimers regarding risks such as clinical trial outcomes, manufacturing, & patent protection.
Genmab owns trademarks including Genmab, HuMax, DuoBody, HexaBody, DuoHexaBody, HexElect, & KYSO.
A specific attachment titled "121126_CA49_Managerial Employee Transactions" accompanies this disclosure.